HT
MLTX icon

Headlands Technologies’s MoonLake Immunotherapeutics MLTX Stock Holding History

Headlands Technologies’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Sell
57,087
-40,046
-41% -$726K 0.12% 218
2026
Q1 		$1.81M Buy
+97,133
New +$1.61M 0.21% 102
2024
Q1 		– Sell
-90
Closed -$5.43K – 1435
2023
Q4 		$5.43K Buy
+90
New +$4.64K ﹤0.01% 824

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Headlands Technologies's MLTX Position: Q2 2026 in Review

Headlands Technologies reduced its MoonLake Immunotherapeutics (MLTX) stake by 41% in Q2 2026, selling an estimated $726K and leaving 57,087 shares worth $1.11M. The position accounts for 0.12% of the portfolio, ranked #218.

Headlands Technologies first reported a position in MLTX in Q4 2023 and has held it in 3 quarters since. The position peaked at $1.81M in Q1 2026. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Headlands Technologies held 57,087 shares of MoonLake Immunotherapeutics worth $1.11M as of Q2 2026.
  • Headlands Technologies sold 40,046 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $726K.
  • MoonLake Immunotherapeutics made up 0.12% of Headlands Technologies's portfolio in Q2 2026, its #218 holding.
  • Headlands Technologies first reported a position in MoonLake Immunotherapeutics in Q4 2023 and has held it in 3 quarters since.
  • Headlands Technologies's MoonLake Immunotherapeutics position peaked at $1.81M in Q1 2026.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.